サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784889

先端巨大症治療の世界市場

Acromegaly Treatment

出版日
ページ情報
英文 297 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
先端巨大症治療の世界市場
出版日: 2025年08月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 297 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

先端巨大症治療の世界市場は2030年までに17億米ドルに到達

2024年に13億米ドルと推定される先端巨大症治療の世界市場は、2024～2030年の分析期間においてCAGR 3.9%で成長し、2030年には17億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるソマトスタチン類似体は、CAGR 3.2%を記録し、分析期間終了時には6億950万米ドルに達すると予測されます。GHRAセグメントの成長率は、分析期間中CAGR 3.9%と推定されます。

米国市場は3億6,750万米ドルと推定、中国はCAGR 7.0％で成長予測

米国の先端巨大症治療市場は、2024年に3億6,750万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3億4,010万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と3.0%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の先端巨大症治療市場- 主要動向と促進要因まとめ

先端巨大症とは何か、なぜ効果的な治療が不可欠なのか？

先端巨大症は、まれではあるが、成長ホルモン（GH）の過剰産生によって引き起こされる深刻なホルモン障害であり、典型的には良性の下垂体腫瘍が原因です。未治療のまま放置すると、心血管疾患、糖尿病、関節炎、臓器肥大などの重篤な合併症を引き起こす可能性があります。早期かつ効果的な治療の必要性から、先端巨大症治療市場は内分泌学の焦点となっています。主な治療選択肢には、下垂体腫瘍の外科的切除、ソマトスタチン類似体（SSA）、ドパミンアゴニスト、GH受容体拮抗薬などの内科的治療、手術や薬物療法が不十分な場合の放射線療法などがあります。診断の進歩や疾患に対する理解の深まりにより、先端巨大症はより早い段階で発見されるようになり、GHレベルをコントロールするだけでなく、症状を緩和し、患者のQOLを改善する効果的な治療に対する需要が高まっています。

技術的・薬学的進歩は先端巨大症治療をどのように変革しているか？

先端巨大症治療を取り巻く環境は、特に薬理学的および外科的アプローチにおいて、目覚ましい技術革新を目の当たりにしてきました。オクトレオチドやランレオチドなどの長時間作用型ソマトスタチン類似体の開発により、必要な注射の頻度が減り、患者のコンプライアンスが大幅に改善されました。GH受容体拮抗薬であるペグビソマントなどの新しい治療法は、IGF-1レベルを正常化し、SSAに抵抗性の患者の症状を管理する上で、非常に優れた有効性を示しています。また、遺伝子や分子のプロファイリングによって、臨床医が個々の患者のニーズに基づいて治療をオーダーメイドできるようになり、個別化医療も人気を集めています。外科領域では、高度な画像診断と神経ナビゲーションシステムに支えられた経蝶形骨手術のような低侵襲技術が、回復時間とリスクを最小限に抑えながら手術成績を向上させています。さらに、遠隔医療と遠隔モニタリングツールの出現は、ホルモンレベルと治療効果の継続的モニタリングを可能にし、患者管理に革命をもたらしました。これらの進歩は、総合的に先端巨大症患者の標準治療を向上させ、良好な転帰をもたらし、治療市場の成長を促進しています。

市場を形成している地域と患者層は？

先端巨大症の有病率は世界的にばらつきがあり、診断率や治療アクセスの地域差が市場に大きな影響を与えています。現在、北米と欧州が先端巨大症治療市場を独占しているが、これは強固なヘルスケア・インフラ、高い認知度、高度な診断・治療ツールへのアクセスの普及が背景にあります。これらの地域はまた、大手製薬会社の存在や、治療効果の向上を目指した広範な研究開発活動の恩恵も受けています。一方、アジア太平洋、ラテンアメリカ、中東の新興市場は、ヘルスケア支出の増加、疾患に対する意識の高まり、専門医療へのアクセスの改善により、急速な成長を遂げています。患者の人口統計によると、先端巨大症は主に30～50歳の成人に発症するが、症状が徐々に現れるため診断が遅れることが多いです。啓蒙キャンペーンやスクリーニング・プログラムを通じて早期発見を強化する取り組みが患者層を再形成し、各地域で的を絞った治療への需要を高めています。

先端巨大症治療市場の成長を促進する要因とは？

先端巨大症治療市場の成長は、薬理療法の進歩、疾患に対する認識の高まり、高度な診断ツールの利用可能性の拡大など、いくつかの要因によって牽引されています。長時間作用型ソマトスタチン類似体やGH受容体拮抗薬などの新規薬剤の開発により、先端巨大症患者、特に従来の治療に抵抗性を示す患者の治療成績が大幅に改善しました。ヘルスケア組織や患者支援団体による啓発キャンペーンの高まりは、この疾患の早期診断と効果的な管理を促進する上で重要な役割を果たしています。低侵襲手術手技の採用や画像技術の向上により、治療精度がさらに向上し、合併症や回復に要する時間が短縮されています。さらに、新興市場におけるヘルスケア・インフラへの投資の増加は、専門的な内分泌学治療へのアクセスを拡大し、これらの地域における市場成長を牽引しています。先端巨大症管理に遠隔医療とデジタルヘルス・ソリューションが統合されたことで、遠隔診察とモニタリングが容易になり、世界中の患者のケアの継続性が確保されたことも、市場拡大に寄与しています。

セグメント

薬剤タイプ（ソマトスタチン類似体、GHRA、その他の薬剤タイプ）、エンドユーザー（病院・診療所エンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • Chiesi USA, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Ipsen Biopharmaceuticals, Inc.
  • Ipsen Pharma
  • Lupin Ltd.
  • Novartis AG
  • Peptron
  • Pfizer, Inc.
  • Recordati Rare Diseases, Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP28961

Global Acromegaly Treatment Market to Reach US$1.7 Billion by 2030

The global market for Acromegaly Treatment estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.7 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Somatostatin Analogs, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$609.5 Million by the end of the analysis period. Growth in the GHRA segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$367.5 Million While China is Forecast to Grow at 7.0% CAGR

The Acromegaly Treatment market in the U.S. is estimated at US$367.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$340.1 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Acromegaly Treatment Market - Key Trends & Drivers Summarized

What Is Acromegaly, and Why Is Effective Treatment Essential?

Acromegaly is a rare but serious hormonal disorder caused by excessive production of growth hormone (GH), typically due to a benign pituitary gland tumor. If left untreated, the condition can lead to severe complications, including cardiovascular disease, diabetes, arthritis, and organ enlargement. The necessity for early and effective treatment has made the acromegaly treatment market a focal point in endocrinology. The primary treatment options include surgical removal of the pituitary tumor, medical therapies like somatostatin analogs (SSAs), dopamine agonists, and GH receptor antagonists, as well as radiation therapy for cases where surgery or medications are insufficient. With advancements in diagnostics and an increased understanding of the disease, acromegaly is now being identified at earlier stages, leading to a growing demand for effective treatments that not only control GH levels but also alleviate symptoms and improve patient quality of life.

How Are Technological and Pharmacological Advancements Transforming Acromegaly Treatment?

The acromegaly treatment landscape has witnessed remarkable innovations, particularly in pharmacological and surgical approaches. The development of long-acting somatostatin analogs, such as octreotide and lanreotide, has significantly improved patient compliance by reducing the frequency of injections required. Emerging therapies, such as pegvisomant, a GH receptor antagonist, have shown exceptional efficacy in normalizing IGF-1 levels and managing symptoms in patients resistant to SSAs. Personalized medicine is also gaining traction, with genetic and molecular profiling enabling clinicians to tailor treatments based on individual patient needs. In the surgical domain, minimally invasive techniques such as transsphenoidal surgery, supported by advanced imaging and neuronavigation systems, have enhanced surgical outcomes while minimizing recovery time and risks. Additionally, the advent of telemedicine and remote monitoring tools has revolutionized patient management, enabling continuous monitoring of hormone levels and treatment efficacy. These advancements have collectively elevated the standard of care for acromegaly patients, driving positive outcomes and fostering growth in the treatment market.

Which Regions and Patient Demographics Are Shaping the Market?

The prevalence of acromegaly varies globally, with regional differences in diagnosis rates and treatment accessibility significantly influencing the market. North America and Europe currently dominate the acromegaly treatment market, driven by robust healthcare infrastructure, high awareness levels, and widespread access to advanced diagnostic and therapeutic tools. These regions also benefit from the presence of major pharmaceutical companies and extensive research and development activities aimed at improving treatment efficacy. In contrast, emerging markets in Asia-Pacific, Latin America, and the Middle East are witnessing rapid growth due to increasing healthcare expenditures, rising disease awareness, and improving access to specialized care. Patient demographics reveal that acromegaly primarily affects adults aged 30 to 50, although delayed diagnosis is common due to the gradual onset of symptoms. Efforts to enhance early detection through awareness campaigns and screening programs are reshaping the patient pool, driving greater demand for targeted treatments across regions.

What Factors Are Driving Growth in the Acromegaly Treatment Market?

The growth in the Acromegaly Treatment market is driven by several factors, including advancements in pharmacological therapies, increasing awareness of the condition, and the growing availability of advanced diagnostic tools. The development of novel drugs, such as long-acting somatostatin analogs and GH receptor antagonists, has significantly improved treatment outcomes for patients with acromegaly, particularly those resistant to conventional therapies. Rising awareness campaigns by healthcare organizations and patient advocacy groups have played a crucial role in promoting early diagnosis and effective management of the disease. The adoption of minimally invasive surgical techniques and improved imaging technologies has further enhanced treatment precision, reducing complications and recovery times. Additionally, increasing investments in healthcare infrastructure in emerging markets have expanded access to specialized endocrinology care, driving market growth in these regions. The integration of telemedicine and digital health solutions into acromegaly management has also contributed to market expansion by facilitating remote consultations and monitoring, ensuring continuity of care for patients worldwide.

SCOPE OF STUDY:

The report analyzes the Acromegaly Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Somatostatin Analogs, GHRA, Other Drug Types); End-Use (Hospitals & Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 63 Featured) -

  • Chiesi USA, Inc.
  • Crinetics Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Ipsen Biopharmaceuticals, Inc.
  • Ipsen Pharma
  • Lupin Ltd.
  • Novartis AG
  • Peptron
  • Pfizer, Inc.
  • Recordati Rare Diseases, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Acromegaly Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Early Diagnosis of Pituitary Disorders Drives Demand for Acromegaly Treatment
    • Expansion of Endocrinology and Rare Disease Specialties Throws the Spotlight on Timely Acromegaly Management
    • Increased Adoption of Somatostatin Analogs Strengthens First-Line Therapeutic Use in Hormonal Regulation
    • Technological Advancements in MRI and IGF-1 Testing Enhance Detection and Monitoring Capabilities
    • Regulatory Approvals for Long-Acting Injectables and Depot Formulations Spur Patient Adherence
    • Growth in Use of GH Receptor Antagonists Propels Market for Second-Line and Resistant Case Therapies
    • Improved Reimbursement and Access to Biologics Encourages Widespread Treatment Initiation
    • Development of Combination Drug Therapies Expands Personalized Treatment Pathways
    • Emergence of Oral Somatostatin Formulations Enhances Convenience and Quality of Life for Patients
    • Integration of Endocrinology and Neurosurgery Supports Multidisciplinary Care Models
    • Increasing Global Research in Pituitary Tumor Genetics Strengthens Precision Medicine Applications
    • Rising Number of Surgical Interventions Promotes Long-Term Post-Operative Pharmacologic Management
    • Expansion of Rare Disease Advocacy Networks Drives Diagnosis and Access in Underserved Populations
    • Availability of Disease-Specific Patient Registries Supports Real-World Evidence and Market Development
    • Strategic Collaborations Between Pharma and Academic Institutions Accelerate Therapeutic Innovation
    • Adoption of Digital Health Tools and Remote Monitoring Enhances Patient Follow-Up and Treatment Adjustment
    • Emerging Biosimilars and Competitive Biologics Landscape Improves Market Accessibility
    • Public Health Initiatives Focused on Endocrine Disorders Create Awareness in Primary Care Settings
    • Focus on Long-Term Disease Burden Reduction Sustains Investment in Safe and Effective Therapeutic Pipelines
    • Global Expansion of Reference Centers for Hormonal Disorders Strengthens Clinical Capacity and Treatment Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acromegaly Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acromegaly Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for GHRA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for GHRA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for GHRA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Acromegaly Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Acromegaly Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Acromegaly Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Acromegaly Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Acromegaly Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Acromegaly Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Acromegaly Treatment by Drug Type - Somatostatin Analogs, GHRA and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Acromegaly Treatment by Drug Type - Percentage Breakdown of Value Sales for Somatostatin Analogs, GHRA and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Acromegaly Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Acromegaly Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION